1030 Massachusetts Avenue
Tel: (781) 806-6245
About Obsidian Therapeutics
Obsidian Therapeutics is pioneering engineered cell and gene therapies to deliver transformative outcomes for patients for the treatment of cancer and other diseases. Obsidian’s programs apply our CytoDRiVETM technology in Cell and Gene therapy products to control expression of proteins for enhanced therapeutic efficacy and safety. Obsidians’ lead program is currently in clinical development for the treatment of patients with metastatic melanoma and other solid tumors.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
We’re proud of our diverse talented team and committed to cultivating an environment where each person feels a strong sense of belonging and is supported to continuously learn and contribute their best work. Our research team is based in the heart of Cambridge, MA, and our Technical Development, Manufacturing & Quality team is based in our new facility in Bedford, MA. We offer competitive salary and benefits, and potential for employee ownership through stock options.
46 articles about Obsidian Therapeutics
Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments
Company also adds Dr. Parameswaran Hari as Chief Development Officer and appoints Dr. Matthew Norkunas to Board of Directors.
Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its recent cytoDRiVE® platform and pipeline advances during the poster sessions at the upcoming SITC Annual Meeting 2022.
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
Obsidian Therapeutics, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties' multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian's cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.
FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
MD Anderson and Obsidian Therapeutics announce FDA Clearance of IND application for novel TIL therapy OBX-115
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022
Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022.
Obsidian Therapeutics to Present Preclinical Data from cytoTIL15™ Program at the American Associate of Cancer Research (AACR) Annual Meeting 2022
Obsidian Therapeutics, Inc. preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022.
Obsidian Therapeutics, Inc. today announced that Maria Fardis , Ph.D., has assumed the role of Chair of Obsidian's Board of Directors.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
1/11/2022The emerging generation of precision gene therapies addresses what has been one of this genre’s greatest challenges to date: the risk of unintended consequences.
11/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, announced the appointment of Heidi Hagen to its Board of Directors.
Obsidian Therapeutics to Present In Vivo Anti-Tumor Efficacy Data from Novel Engineered cytoTIL15 Program at SITC 2021
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
10/22/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Obsidian Therapeutics, Inc. today announced the appointment of Maria Fardis , Ph.D., to its Board of Directors.
Obsidian Therapeutics To Present Preclinical Data From cytoTIL15 Program at the European Society for Medical Oncology Congress 2021
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology Congress, which will be hosted virtually September 16-21, 2021.
9/15/2021Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover Fund (TCGX).
Obsidian Therapeutics and three other pharmaceutical companies announced successful Series B raises to propel pipeline candidates further down the track toward clinical studies and approvals.